Cligosiban (INNTooltip International Nonproprietary Name; developmental code names IX-01 and PF-3274167) is an oxytocin receptor antagonist which is or was under development for the treatment of premature ejaculation. It is taken orally. The drug is a small molecule or non-peptide and is a potent, highly selective, and brain-penetrant antagonist of the oxytocin receptor. Cligosiban was originated by Pfizer and is under development by Ixchelsis and Chorus Group. As of December 2019, it is in phase 2 clinical trials. However, another source lists the drug's development as having been discontinued. The drug failed to show effectiveness in a phase 2b trial.
See also List of investigational sexual dysfunction drugs Epelsiban
References